CJC-1295 is one of the most widely used growth hormone peptides in clinical practice. Unlike short-acting GHRH analogues, its modified structure provides extended biological activity that sustains GH stimulation over days rather than hours. Understanding its specific characteristics helps you have a more informed conversation with your physician about whether it belongs in your protocol.
What CJC-1295 Does
CJC-1295 is a synthetic analogue of GHRH (growth hormone-releasing hormone) with a drug affinity complex (DAC) modification that significantly extends its half-life from minutes to approximately 6 to 8 days.
When injected, CJC-1295 binds to pituitary GHRH receptors and sustains an elevated GH release stimulus over the following several days. This produces:
- Elevated basal GH secretion throughout the week
- Increased IGF-1 production from the liver in response to chronic GH elevation
- Maintained pulsatile GH architecture (natural feedback preserved, unlike direct HGH)
Key Benefits
IGF-1 Elevation
CJC-1295's primary measurable outcome is a sustained elevation in serum IGF-1. Published studies have shown IGF-1 increases of 200 to 300 percent above baseline with weekly CJC-1295 dosing, persisting for the duration of treatment. This elevation drives the anabolic and metabolic benefits.
Body Composition Improvement
Elevated IGF-1 from CJC-1295 treatment is associated with:
- Increased lean muscle mass (primarily through satellite cell activation and protein synthesis)
- Reduced body fat (particularly visceral fat)
- Improved muscle-to-fat ratio over 3 to 6 months
Recovery and Repair
IGF-1 stimulates fibroblast proliferation and collagen synthesis, accelerating recovery from training and injury. Athletes on CJC-1295 protocols typically report significantly improved recovery times and reduced post-training soreness.
Sleep Quality
CJC-1295 supports deeper, more restorative sleep by amplifying the nocturnal GH pulse that naturally occurs during slow-wave sleep stages.
Metabolic Health
Sustained IGF-1 elevation improves insulin sensitivity in adipose tissue and muscle, contributing to better blood sugar regulation and reduced visceral fat accumulation.
Dosing Considerations
Standard clinical dosing of CJC-1295 with DAC involves subcutaneous injection once or twice weekly. This extended interval is possible because of the peptide's long half-life.
At Longegra, dosing is based on:
- Baseline IGF-1: Lower baseline levels may warrant higher starting doses
- Clinical goals: Body recomposition, recovery, or anti-aging have slightly different target IGF-1 ranges
- Response at three months: Follow-up IGF-1 testing guides dose adjustment
CJC-1295 is most commonly combined with ipamorelin (a ghrelin receptor agonist) for synergistic GH pulsatility, as the two peptides act through complementary mechanisms.
Side Effects
CJC-1295 is generally well tolerated. The most commonly observed effects:
- Water retention: Mild fluid retention in the first two to four weeks, related to GH's effect on kidney fluid handling. Usually self-resolving.
- Joint discomfort: Some patients experience mild wrist or joint discomfort in the first few weeks, also related to GH activity. Typically resolves with continued use.
- Injection site reactions: Minor redness or tenderness at the injection site is occasionally reported.
- Tingling or numbness: Occasionally reported in extremities, related to mild water retention effects on peripheral nerves.
Serious adverse effects have not been documented at therapeutic doses in published studies.
Who Should Not Use CJC-1295
CJC-1295 requires physician assessment before use. It is generally not appropriate for:
- Active malignancy (GH axis stimulation is contraindicated in known cancer)
- Confirmed pituitary tumour or pituitary disease
- Pregnancy or breastfeeding
- Diabetic retinopathy (IGF-1 elevation can potentially affect retinal vasculature)
Frequently Asked Questions (FAQs)
IGF-1 elevation is measurable at three months of consistent use in most patients. Earlier functional benefits (sleep, recovery) are often noticed within four to eight weeks.
